Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Date: Monday, May 5, 2025 Time: 2:30 p.m. Eastern Time Location: Metro Toronto Convention Centre, Toronto Webcast: https://event.summitcast.com/view/hG2KhRan38C8o5wZiWyxNK/6hRWPTiDpf8iZLFakhbeJ6 ...

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is ...

Terpenes, derived from the Cannabis sativa plant, may be the basis of a medication for fibromyalgia and post-surgical pain ...

With a watery consistency, this formula is tops at providing weightless hydration that won't leave behind an unflattering ...

Review highlights how vitamin D, particularly its active form calcitriol, modulates immune responses, inflammation, and tumor ...

Modern medicine is experiencing a period of significant advancements and innovations, and at its core is radiopharmaceuticals ...

Suzuki, R. (2025) Evaluation of the Hair Growth-Promoting Effects of Combined Treatment with Hair Growth Stimulants. Health, ...

In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel ...

Furthermore, the alpha and beta hemispheric asymmetry in the centroparietal area was significantly higher in the UVP and VUVP conditions as compared to the NVP condition between 500 ms and 2000 ms ...